AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28660990 — intervention group
Group type: COMPARATOR
Intervention: External jugular vein venepuncture
Number of subjects: 39
Study 25100052 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily alcohol use
Number of subjects: 0
Study 23303903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (2.0 g daily for 28 days)
Number of subjects: 20
Study 21676960 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-rated scale
Number of subjects: 403
Study 21676960 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-rated scale
Number of subjects: 403
Study 21676960 — intervention group
Group type: EXPERIMENTAL
Intervention: Theorized factor structure
Number of subjects: 403
Study 18930094 — intervention group
Group type: EXPERIMENTAL
Intervention: PfCP2.9/ISA 720 (5, 20, and 50 microg)
Number of subjects: 70
Study 16540287 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 10 mg
Number of subjects: 3
Study 16540287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampiroxicam 27 mg
Number of subjects: 3
Study 16540287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 15451148 — intervention group
Group type: EXPERIMENTAL
Intervention: HF (Heart Failure)
Number of subjects: 15078
Study 10419345 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy of normal-appearing urothelium in low-risk tumors
Number of subjects: 995
Study 10419345 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy of normal-appearing urothelium in intermediate- and high-risk tumors
Number of subjects: 995
Study 7742745 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu EPO (300 units per kg/day given thrice weekly by intravenous injection)
Number of subjects: 91
Study 7742745 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhu EPO)
Number of subjects: 91
Study 7742745 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu EPO group
Number of subjects: 91
Study 7742745 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu EPO
Number of subjects: 91
Study 2285274 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine (100 mg daily)
Number of subjects: 228
Study 2285274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 7433474 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg doxycycline daily for 10 days
Number of subjects: 46
Study 7433474 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg doxycycline on the first day and 100 mg on subsequent days for 8 days
Number of subjects: 46
Study 7433474 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 46
Study 30707360 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural cycle with spontaneous ovulation
Number of subjects: 471
Study 30707360 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural cycle with hCG for ovulation induction
Number of subjects: 471
Study 30707360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement cycle (HRC)
Number of subjects: 471
Study 30208454 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam, 4.5 g, every 6 hours (n=188 participants)
Number of subjects: 391
Study 30208454 — intervention group
Group type: COMPARATOR
Intervention: Meropenem, 1 g, every 8 hours (n=191 participants)
Number of subjects: 391
Study 30208454 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 391
Study 30208454 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 391
Study 27231056 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented group (200,000 IU of retinyl palmitate)
Number of subjects: 88
Study 27231056 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 24644139 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy shot
Number of subjects: 10
Study 24644139 — intervention group
Group type: COMPARATOR
Intervention: Noncaffeinated energy shot
Number of subjects: 10
Study 22575072 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ED (consume ≥10 foods ≤1.0 kcal/g dietary ED and ≤2 foods ≥3.0 kcal/g dietary ED per day)
Number of subjects: 44
Study 22575072 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Energy, Low-Fat (1,200 to 1,500 kcal/day, ≤30% energy from fat)
Number of subjects: 44
Study 22575072 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-ED, Low-Energy, Low-Fat
Number of subjects: 44
Study 19688393 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus-first method using ultrasonic dissection
Number of subjects: 243
Study 17942381 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium therapy
Number of subjects: 1098
Study 17942381 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip T-score
Number of subjects: 1098
Study 17942381 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture odds at zero T-score
Number of subjects: 1098
Study 17942381 — intervention group
Group type: EXPERIMENTAL
Intervention: Age increase
Number of subjects: 1098
Study 17942381 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent fracture
Number of subjects: 1098
Study 17942381 — intervention group
Group type: EXPERIMENTAL
Intervention: Unit fall in hip T-score
Number of subjects: 1098
Study 17942381 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for fracture risk estimation
Number of subjects: 1098
Study 16291885 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200-400 mg/day)
Number of subjects: 40
Study 16291885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12016631 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 236
Study 10561254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 220
Study 10561254 — intervention group
Group type: COMPARATOR
Intervention: MAB
Number of subjects: 220
Study 7745320 — intervention group
Group type: EXPERIMENTAL
Intervention: High tie of the inferior mesenteric artery
Number of subjects: 62
Study 7745320 — intervention group
Group type: COMPARATOR
Intervention: Low tie of the inferior mesenteric artery
Number of subjects: 62
Study 31740722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue microarray scoring using DAKO 28‐8 immunohistochemistry assay
Number of subjects: 2008
Study 31740722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue microarray scoring
Number of subjects: 2008
Study 28471973 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 34
Study 28471973 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 34
Study 28471973 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (VCV and PCV)
Number of subjects: 34
Study 23264555 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) treatment
Number of subjects: 115
Study 21496251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group participating in six, two-hour face-to-face sessions held over eight weeks.
Number of subjects: 0
Study 21496251 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group.
Number of subjects: 0
Study 19943976 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care program combining patient-directed and workplace-directed interventions provided by a multidisciplinary team including a clinical occupational physician.
Number of subjects: 37
Study 19943976 — intervention group
Group type: EXPERIMENTAL
Intervention: Role of the clinical occupational physician in the RTW process.
Number of subjects: 37
Study 19943976 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-investment as a barrier for implementation reported by the multidisciplinary team.
Number of subjects: 37
Study 17982746 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational Entonox
Number of subjects: 150
Study 17982746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pethidine
Number of subjects: 150
Study 17982746 — intervention group
Group type: COMPARATOR
Intervention: Inhalational compressed air
Number of subjects: 150
Study 15248189 — intervention group
Group type: EXPERIMENTAL
Intervention: Onofin-K (200 mg)
Number of subjects: 24
Study 15248189 — intervention group
Group type: COMPARATOR
Intervention: Nizoral (200 mg)
Number of subjects: 24
Study 11317474 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg fluvastatin twice per day over a 3-month period (n = 14)
Number of subjects: 21
Study 11317474 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 21
Study 9393270 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAAs (Aminoleban EN) 100 g per day for 1 year
Number of subjects: 150
Study 9393270 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 8194956 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevention programme integrated with other school subjects and parental involvement
Number of subjects: 0
Study 8194956 — intervention group
Group type: COMPARATOR
Intervention: Matched control groups
Number of subjects: 0
Study 3583472 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphylong administered after a hot evening meal
Number of subjects: 0
Study 3583472 — intervention group
Group type: COMPARATOR
Intervention: Euphylong administered before a cold evening meal
Number of subjects: 0
Study 28401587 — intervention group
Group type: EXPERIMENTAL
Intervention: Get Busy Get Better (GBGB)
Number of subjects: 208
Study 28401587 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 208
Study 27519921 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV combined with HFNC (pressure support=10, PEEP=5, FiO2=100% + flow=60 L/min, FiO2=100%)
Number of subjects: 50
Study 27519921 — intervention group
Group type: COMPARATOR
Intervention: NIV alone (reference group)
Number of subjects: 50
Study 27519921 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV combined with HFNC
Number of subjects: 50
Study 24730354 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic plus resistance training (AT + RT)
Number of subjects: 139
Study 24730354 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 139
Study 22502790 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM 20 mg daily orally (arm A)
Number of subjects: 176
Study 22502790 — intervention group
Group type: COMPARATOR
Intervention: TAM 10 mg daily starting simultaneously with bicalutamide (arm B)
Number of subjects: 176
Study 20398868 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine angiographic follow-up
Number of subjects: 0
Study 20398868 — intervention group
Group type: COMPARATOR
Intervention: Clinical follow-up alone
Number of subjects: 0
Study 20398868 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-revascularized patients with nonischemic intermediate lesions
Number of subjects: 0
Study 20398868 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who had TLR at angiographic follow-up
Number of subjects: 0
Study 17869051 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-session brief intervention (motivational enhancement therapy)
Number of subjects: 40
Study 17869051 — intervention group
Group type: COMPARATOR
Intervention: 3-month delayed-treatment control condition
Number of subjects: 40
Study 16162709 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 29
Study 12846760 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 14
Study 12846760 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 14
Study 10097506 — intervention group
Group type: EXPERIMENTAL
Intervention: Atarax (hydroxyzine) 50 mg daily for 28 days
Number of subjects: 55
Study 10097506 — intervention group
Group type: EXPERIMENTAL
Intervention: Atarax (hydroxyzine)
Number of subjects: 55
Study 8762876 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical acupuncture (experimental group)
Number of subjects: 38
Study 8762876 — intervention group
Group type: COMPARATOR
Intervention: Superficial acupuncture (control group)
Number of subjects: 38
Study 8762876 — intervention group
Group type: COMPARATOR
Intervention: Both groups (irradiated salivary glands)
Number of subjects: 38
Study 1875413 — intervention group
Group type: EXPERIMENTAL
Intervention: Total doses D1, D2, D3, and D4 differing by increments of 4.8 Gy, with all patients receiving two fractions of 1.2 Gy each daily 5 days a week.
Number of subjects: 0
Study 1875413 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen D3 (highest dose)
Number of subjects: 0
Study 1875413 — intervention group
Group type: COMPARATOR
Intervention: Regimen D1
Number of subjects: 0
Study 1875413 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen D2 and D3
Number of subjects: 0
Study 6653395 — intervention group
Group type: EXPERIMENTAL
Intervention: Low opiate use group
Number of subjects: 20
Study 6653395 — intervention group
Group type: EXPERIMENTAL
Intervention: High opiate use group
Number of subjects: 20
Study 6653395 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 20
Study 31751343 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate-oxytocin
Number of subjects: 60
Study 31751343 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol-oxytocin
Number of subjects: 60
Study 29122186 — intervention group
Group type: EXPERIMENTAL
Intervention: IMU-based inclinometer solutions
Number of subjects: 13
Study 29122186 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer-based inclinometers
Number of subjects: 13
Study 26888208 — intervention group
Group type: COMPARATOR
Intervention: Bright white-light treatment (BLT, broad-wavelength light without UV 10,000 lux, irradiance 31.7 Watt/m(2))
Number of subjects: 48
Study 26888208 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band blue light (BLUE, 100 lux, irradiance 1.0 Watt/m(2))
Number of subjects: 48
Study 24419823 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection (3 cc)
Number of subjects: 40
Study 24419823 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (40 mg DepoMedrol)
Number of subjects: 40
Study 22752379 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence imaging using indocyanine green (ICG) with 99(m) technetium-nanocolloid
Number of subjects: 24
Study 22752379 — intervention group
Group type: COMPARATOR
Intervention: Near-infrared fluorescence imaging using indocyanine green (ICG) with 99(m) technetium-nanocolloid and patent blue
Number of subjects: 24
Study 20958144 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Flow rapid(®) nebulizer
Number of subjects: 6
Study 20958144 — intervention group
Group type: COMPARATOR
Intervention: Sidestream(®) nebulizer used alone
Number of subjects: 6
Study 20958144 — intervention group
Group type: EXPERIMENTAL
Intervention: Sidestream(®) nebulizer coupled to a 110‐mL corrugated piece of tubing
Number of subjects: 6
Study 20958144 — intervention group
Group type: EXPERIMENTAL
Intervention: All three nebulizers (e-Flow rapid(®), Sidestream(®) alone, and Sidestream(®) with tubing)
Number of subjects: 6
Study 17211605 — intervention group
Group type: EXPERIMENTAL
Intervention: Local collagen-gentamicin prophylaxis
Number of subjects: 0
Study 17211605 — intervention group
Group type: COMPARATOR
Intervention: Routine intravenous prophylaxis of isoxazolyl-penicillin
Number of subjects: 0
Study 15167592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (100 mg/day)
Number of subjects: 100
Study 15167592 — intervention group
Group type: COMPARATOR
Intervention: Control (no ketoconazole)
Number of subjects: 100
Study 11411734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9582592 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 27
Study 9582592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8018462 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-flurbiprofen 50 mg
Number of subjects: 16
Study 8018462 — intervention group
Group type: COMPARATOR
Intervention: (R)-flurbiprofen 50 mg
Number of subjects: 16
Study 8018462 — intervention group
Group type: COMPARATOR
Intervention: (R)-flurbiprofen 100 mg
Number of subjects: 16
Study 3050904 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg inhaled gallopamil
Number of subjects: 15
Study 3050904 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg inhaled gallopamil
Number of subjects: 15
Study 3050904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30418041 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergames played for 2 weeks
Number of subjects: 337
Study 30418041 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 337
Study 29203509 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self-Help: a low-intensity psychological intervention based on behavioural activation adapted for ASD
Number of subjects: 70
Study 29203509 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 70
Study 25520249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine treatment with diet and exercise
Number of subjects: 9804
Study 25520249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine treatment
Number of subjects: 9804
Study 25520249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9804
Study 24460649 — intervention group
Group type: EXPERIMENTAL
Intervention: PPAR α and PPAR γ polymorphisms (rs1800206, rs1805192, rs3856806)
Number of subjects: 820
Study 24460649 — intervention group
Group type: COMPARATOR
Intervention: V-G haplotype (rs1800206, rs4253778)
Number of subjects: 820
Study 24460649 — intervention group
Group type: COMPARATOR
Intervention: Pro-C haplotype (rs1805192, rs3856806)
Number of subjects: 820
Study 24460649 — intervention group
Group type: EXPERIMENTAL
Intervention: A-T haplotype
Number of subjects: 820
Study 24460649 — intervention group
Group type: EXPERIMENTAL
Intervention: P-T, A-C, A-T haplotypes
Number of subjects: 820
Study 22481313 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-carbohydrate/lower-fat diet (55% CHO, 18% PRO, 27% FAT)
Number of subjects: 61
Study 22481313 — intervention group
Group type: COMPARATOR
Intervention: Lower-carbohydrate/higher-fat diet (43% CHO, 18% PRO, 39% FAT)
Number of subjects: 61
Study 19531226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy‐based blood pressure clinics led by peer health educators with feedback to family physicians
Number of subjects: 0
Study 19531226 — intervention group
Group type: COMPARATOR
Intervention: Usual Practice model
Number of subjects: 0
Study 18166695 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (3 times a week group exercise, 6 hours of fall prevention education, comprehensive falls risk assessment results sent to primary health care provider)
Number of subjects: 453
Study 18166695 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 453
Study 18166695 — intervention group
Group type: COMPARATOR
Intervention: Control group (written materials on falls prevention)
Number of subjects: 453
Study 15468574 — intervention group
Group type: COMPARATOR
Intervention: Single dose of albendazole (400 mg)
Number of subjects: 786
Study 15468574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (1.2 g single dose)
Number of subjects: 786
Study 15468574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (15 mg/kg/day for three days)
Number of subjects: 786
Study 15468574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (three-day regimen)
Number of subjects: 786
Study 15468574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (single dose)
Number of subjects: 786
Study 15468574 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (single dose)
Number of subjects: 786
Study 11799281 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk containing Lactobacillus rhamnosus GG (LGG)
Number of subjects: 594
Study 11799281 — intervention group
Group type: COMPARATOR
Intervention: Normal milk (Control)
Number of subjects: 594
Study 9660039 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron protein succinylate
Number of subjects: 100
Study 9660039 — intervention group
Group type: COMPARATOR
Intervention: Iron hydroxide polymaltose complex
Number of subjects: 100
Study 7635580 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative suggestions
Number of subjects: 60
Study 7635580 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and perioperative suggestions
Number of subjects: 60
Study 7635580 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative suggestions only
Number of subjects: 60
Study 7635580 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 60
Study 2100983 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral cefoxitin (given in three divided doses)
Number of subjects: 197
Study 2100983 — intervention group
Group type: COMPARATOR
Intervention: No parenteral antibiotics (control group)
Number of subjects: 197
Study 150816 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sulfur in Triton X‐100 vehicle
Number of subjects: 52
Study 150816 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sulfur in carbomer 934P vehicle
Number of subjects: 52
Study 150816 — intervention group
Group type: COMPARATOR
Intervention: Triton X‐100 vehicle (control)
Number of subjects: 52
Study 150816 — intervention group
Group type: COMPARATOR
Intervention: Dry patch test (control)
Number of subjects: 52
Study 30674360 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP NF
Number of subjects: 30
Study 30674360 — intervention group
Group type: EXPERIMENTAL
Intervention: θ/β NF
Number of subjects: 30
Study 30674360 — intervention group
Group type: COMPARATOR
Intervention: Control group (attention skills training)
Number of subjects: 30
Study 31421668 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy alone
Number of subjects: 0
Study 31421668 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy combined with corticosteroid injection
Number of subjects: 0
Study 31421668 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28756791 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application intervention for physical activity
Number of subjects: 0
Study 25636341 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 256
Study 25636341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256